Galderma’s First-In-Class Biologic Chases Eczema Spoils
Executive Summary
Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.
You may also be interested in...
Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
Almirall Extends Dermatology Reach With Dermira Lebrikizumab Deal
Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.
Galderma Steps Into Biologics With Chugai Eczema Antibody
Galderma has acquired most global rights to a first-in-class antibody from Chugai that will both strengthen the Swiss skin specialist's atopic dermatitis portfolio and provide its first biologic therapy.